Cancer-associated thrombosis in pediatric patients.

Abstract

Childhood malignancy and especially acute lymphoblastic leukemia are increasingly associated with thromboembolism. The etiology of pediatric cancer associated thrombosis is multifactorial and may reflect a tumor mass effect, tumor thrombi, alterations of the hemostatic system, treatment-related hazards (e.g. procoagulant changes induced by chemotherapy), presence of central venous lines and comorbidities (e.g. inherited thrombophilia). With over 80% cure rates of childhood cancer, strategies for prevention as well as for early diagnosis and optimal treatment of thromboembolism in children with malignancies are of major importance. While the use of therapeutic low molecular weight heparin prevails, prospective studies regarding guidelines for treatment or prevention are currently lacking. This review will address the epidemiology, etiology and risk factors for thrombosis, describe the presently available evidence associated with current therapy, and offer a glimpse into future treatment options.

• Authors: Assaf Arie Barg, Gili Kenet
• Journal: Thrombosis research (Thromb Res) Vol. 191 Suppl 1 Pg. S22-S25 (07 2020) ISSN: 1879-2472 [Electronic] United States
• PMID: 32736773 (Publication Type: Journal Article, Review)
• Copyright: © 2020 Elsevier Ltd. All rights reserved.

Chemical References

• Heparin, Low-Molecular-Weight

Topics

• Child
• Heparin, Low-Molecular-Weight (therapeutic use)
• Humans
• Neoplasms (complications)
• Prospective Studies
• Risk Factors
• Thromboembolism
• Thrombophilia
• Thrombosis (etiology)